Y-mAbs Therapeutics, Inc (YMAB) Receives $31.75 Average PT from Analysts

Share on StockTwits

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) has been assigned a consensus rating of “Buy” from the six research firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $31.75.

YMAB has been the subject of a number of recent research reports. HC Wainwright initiated coverage on shares of Y-mAbs Therapeutics in a research note on Monday, April 1st. They issued a “buy” rating and a $36.00 price objective for the company. Zacks Investment Research raised shares of Y-mAbs Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, March 15th.

Shares of NASDAQ:YMAB opened at $20.92 on Tuesday. Y-mAbs Therapeutics has a 52 week low of $15.17 and a 52 week high of $31.00. The firm has a market capitalization of $715.34 million and a price-to-earnings ratio of -13.95. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.30 and a quick ratio of 13.30.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Friday, March 22nd. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.11). As a group, research analysts expect that Y-mAbs Therapeutics will post -1.93 EPS for the current fiscal year.

In other news, insider Thomas Gad sold 6,000 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $20.61, for a total value of $123,660.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of Y-mAbs Therapeutics by 32.2% in the 4th quarter. FMR LLC now owns 1,626,642 shares of the company’s stock worth $33,086,000 after acquiring an additional 396,000 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Y-mAbs Therapeutics by 20.9% in the 4th quarter. Millennium Management LLC now owns 386,919 shares of the company’s stock worth $7,870,000 after acquiring an additional 67,013 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Y-mAbs Therapeutics by 8.0% in the 1st quarter. BlackRock Inc. now owns 369,159 shares of the company’s stock worth $9,676,000 after acquiring an additional 27,328 shares during the last quarter. Vanguard Group Inc bought a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter worth about $2,260,000. Finally, Vanguard Group Inc. bought a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter worth about $2,260,000. Hedge funds and other institutional investors own 25.36% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Further Reading: What are the qualifications of a portfolio manager?

Analyst Recommendations for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Autoliv  PT Lowered to $62.00 at Buckingham Research
Autoliv PT Lowered to $62.00 at Buckingham Research
Shotspotter  Cut to “Market Perform” at Northland Securities
Shotspotter Cut to “Market Perform” at Northland Securities
Buckingham Research Increases Sonic Automotive  Price Target to $20.00
Buckingham Research Increases Sonic Automotive Price Target to $20.00
Vail Resorts  Earns Market Perform Rating from Analysts at Wells Fargo & Co
Vail Resorts Earns Market Perform Rating from Analysts at Wells Fargo & Co
Johnson Outdoors  Downgraded by Sidoti
Johnson Outdoors Downgraded by Sidoti
Autoliv  Stock Rating Upgraded by Robert W. Baird
Autoliv Stock Rating Upgraded by Robert W. Baird


© 2006-2019 Ticker Report